Magnetic resonance imaging and o-(2-[<sup>18</sup>F]fluoroethyl)-l-tyrosine positron emission tomography for early response assessment of nivolumab and bevacizumab in patients with recurrent high-grade astrocytic glioma.

Neurooncol Adv · 2024 · PMC11630048 · PMID 39659835

Europe PMC DOI

hedged sentence

0.0560

closest p · 1.1× alpha

0.0560

boldest claim

The sentences

borderline significantP = .056so close (0.05 < p ≤ 0.1)

PET RANO classification showed borderline significant median OS in patients with progression vs nonprogression ( P = .056) and response versus nonresponse ( P = .054), see also Table 2 .

also in 11,409 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.